DualityBio tries to float again
The group expects to raise nearly $170m.
ELCC 2025 – J&J takes it to Tagrisso
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
ALX plays the conjugate card
Could a new ADC project distract attention away from evorpacept?
